Please select the option that best describes you:
How would you modify adjuvant therapy for a patient with ER+ HER2+ breast CA with no response to neoadjuvant TCHP and develops pneumonitis on adjuvant TDM-1?
Would you use trastuzumab/pertuzumab, trastuzumab followed by neratinib, or another strategy?
Answer from: Medical Oncologist at Community Practice
Retest tissue for Her2.
No data for cytotoxic chemo but consider ACx4 and adjuvant Traz/pertuz to complete a year and then perhaps Neratinib especially if ER+ive.
Sign in or Register to read more